Skeletal-related events (SREs) are complications of bone metastases and carry a significant
patient and economic burden. Denosumab is a receptor activator of nuclear factor-κB ligand …

From rat studies, human case reports and cohort studies, bisphosphonates seem to impair
renal function. However, when critically reviewing the literature, zoledronate and …

Abstract In ENDEAVOR, carfilzomib (56 mg/m2) and dexamethasone (Kd56) demonstrated
longer progression-free survival (PFS) over bortezomib and dexamethasone (Vd) in patients …

Background Bone complications (pathologic fracture, spinal cord compression, surgery to
bone and radiation to bone) are a common problem in patients with multiple myeloma (MM) …

Objectives Multiple myeloma (MM) is the second most common hematological malignancy.
Progression free survival (PFS) and overall survival (OS) have substantially improved …

Background Renal insufficiency (RI) is a key factor affecting the prognosis of multiple
myeloma (MM) patients. Because the benefit of daratumumab for treating MM patients with …

The phase 3 ARROW study demonstrated that treatment with once-weekly carfilzomib (70
mg/m2) and dexamethasone (once-weekly Kd70 mg/m2) improved progression-free survival …

Objective: A large, pivotal, phase 3 trial in patients with newly diagnosed multiple myeloma
(MM) demonstrated that denosumab, compared with zoledronic acid, was non-inferior for the …

Clinical trials may be inconsistent in their enrollment and reporting of patients with multiple
myeloma (MM) who have renal insufficiency (RI). We performed a systematic review of all …

Aim: The approved indication for denosumab (120 mg) was expanded in 2018 to include
skeletal-related event (SRE) prevention in patients with multiple myeloma (MM). Therefore, a …